Two major problems that limit the success of cancer therapy are the dose limiting normal tissue toxicities and the development of cancer cells that are resistant to the therapeutic agents. Furthermore, patients who develop resistance to one such agent often exhibit cross- resistance to other agents that are structurally and mechanistically dissimilar. It has been shown that many key anticancer agents produce reactive oxygen radicals. In addition, cells that develop resistance to an oxygen-radical-generating agent also exhibit cross-resistance to other oxygen-radical-generating agents that are structurally unrelated. PI hypothesizes that much of the normal tissue damage associated with cancer therapy is attributed to the production of oxygen radicals and that protection against oxygen radicals may account for the development of cancer cells that are resistant to many therapeutic agents. The goal of the proposed research project is to investigate the role of antioxidant enzyme manganese superoxide dismutase (MnSOD) in the development of resistance in cancer and toxicity to normal tissue during cancer therapy. Specifically, the investigators will determine whether increased MnSOD activity will lead to resistance in cancer cells and/or protection of normal tissue from the toxicity of adriamycin (ADR), tumor necrosis factor (TNF) and (-radiation, three structurally unrelated therapeutic agents known to generate oxygen radicals. The investigation will be undertaken in four phases. First, the endogenous level of MnSOD in tumor cells will be modulated by transfection of sense and antisense MnSOD genes. The incorporation, expression, and localization of the transfected genes and their products will be monitored at all levels from the gene to active protein. The effect of MnSOD transfection on cell growth, respiration, and expression of other cellular proteins will be monitored. Second, the effect of ADR, TNF and (-radiation on cell kill, macromolecule synthesis, lipid peroxidation, and mitochondrial function will be examined in the parental tumor cells and tumor cells with modulated levels of MnSOD in vitro. Third, the effect of ADR, TNF and (-radiation on heart tissue in normal and transgenic mice expressing a range of elevated levels of human MnSOD will be examined by histological and biochemical methods. The effect of ADR, TNF and (- radiation on the livers of transgenic mice, which do not express human MnSOD will be used as a negative control. Finally, cancer cells with modulated levels of MnSOD will be transplanted into both control and transgenic mice, and the effect of ADR, TNF and (-radiation in both cancer cells and heart tissue of cancer-bearing mice will be assessed by the same methods. The results from this study may contribute significantly to the understanding of cancer cell resistance and defense of normal tissue against the toxic effects of oxygen radicals generated by therapeutic agents. It is possible that new concepts of cancer therapy such as the development of specific measures to induce MnSOD in normal tissue or block the induction of MnSOD in tumor cells may lead to improvement of cancer treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA059835-03S1
Application #
6018117
Study Section
Chemical Pathology Study Section (CPA)
Program Officer
Wolpert, Mary K
Project Start
1995-07-01
Project End
1999-06-30
Budget Start
1997-07-01
Budget End
1999-06-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Kentucky
Department
Pharmacology
Type
Other Domestic Higher Education
DUNS #
832127323
City
Lexington
State
KY
Country
United States
Zip Code
40506
Chaiswing, Luksana; Cole, Marsha P; St Clair, Daret K et al. (2004) Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury. Toxicol Pathol 32:536-47
Dhar, Sanjit K; Lynn, Bert C; Daosukho, Chotiros et al. (2004) Identification of nucleophosmin as an NF-kappaB co-activator for the induction of the human SOD2 gene. J Biol Chem 279:28209-19
Xu, Yong; Porntadavity, Sureerut; St Clair, Daret K (2002) Transcriptional regulation of the human manganese superoxide dismutase gene: the role of specificity protein 1 (Sp1) and activating protein-2 (AP-2). Biochem J 362:401-12
Daosukho, Chotiros; Kiningham, Kelley; Kasarskis, Edward J et al. (2002) Tamoxifen enhancement of TNF-alpha induced MnSOD expression: modulation of NF-kappaB dimerization. Oncogene 21:3603-10
Maragos, W F; Jakel, R; Chesnut, D et al. (2000) Methamphetamine toxicity is attenuated in mice that overexpress human manganese superoxide dismutase. Brain Res 878:218-22
Sullivan, P G; Bruce-Keller, A J; Rabchevsky, A G et al. (1999) Exacerbation of damage and altered NF-kappaB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury. J Neurosci 19:6248-56
Yen, H C; Oberley, T D; Gairola, C G et al. (1999) Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice. Arch Biochem Biophys 362:59-66
Xu, Y; Krishnan, A; Wan, X S et al. (1999) Mutations in the promoter reveal a cause for the reduced expression of the human manganese superoxide dismutase gene in cancer cells. Oncogene 18:93-102
Kiningham, K K; Oberley, T D; Lin, S et al. (1999) Overexpression of manganese superoxide dismutase protects against mitochondrial-initiated poly(ADP-ribose) polymerase-mediated cell death. FASEB J 13:1601-10
Xu, Y; Kiningham, K K; Devalaraja, M N et al. (1999) An intronic NF-kappaB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-alpha and interleukin-1beta. DNA Cell Biol 18:709-22

Showing the most recent 10 out of 15 publications